MXPA05012061A - Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad. - Google Patents
Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.Info
- Publication number
- MXPA05012061A MXPA05012061A MXPA05012061A MXPA05012061A MXPA05012061A MX PA05012061 A MXPA05012061 A MX PA05012061A MX PA05012061 A MXPA05012061 A MX PA05012061A MX PA05012061 A MXPA05012061 A MX PA05012061A MX PA05012061 A MXPA05012061 A MX PA05012061A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- aryl alkyl
- preparation
- treatment
- alkyl acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Esta invencion se refiere a ciertos compuestos de acidos de aril alquilo, a las composiciones y metodos para tratar o prevenir la obesidad y enfermedades relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46961903P | 2003-05-09 | 2003-05-09 | |
PCT/US2004/014036 WO2004100881A2 (en) | 2003-05-09 | 2004-05-06 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05012061A true MXPA05012061A (es) | 2006-02-22 |
Family
ID=33452304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05012061A MXPA05012061A (es) | 2003-05-09 | 2004-05-06 | Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad. |
Country Status (24)
Country | Link |
---|---|
US (5) | US7091228B2 (es) |
EP (1) | EP1633722B1 (es) |
JP (1) | JP4759517B2 (es) |
KR (1) | KR20060009916A (es) |
CN (1) | CN1816531A (es) |
AR (1) | AR044152A1 (es) |
AT (1) | ATE518841T1 (es) |
AU (1) | AU2004238258A1 (es) |
BR (1) | BRPI0410170A (es) |
CA (1) | CA2524470A1 (es) |
CL (1) | CL2004000969A1 (es) |
EC (1) | ECSP056210A (es) |
ES (1) | ES2369220T3 (es) |
GT (1) | GT200400092A (es) |
MA (1) | MA27843A1 (es) |
MX (1) | MXPA05012061A (es) |
NO (1) | NO20055832L (es) |
NZ (1) | NZ543993A (es) |
PE (1) | PE20050265A1 (es) |
RU (1) | RU2357959C2 (es) |
TW (1) | TW200510334A (es) |
UY (1) | UY28314A1 (es) |
WO (1) | WO2004100881A2 (es) |
ZA (1) | ZA200509883B (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1805156B1 (en) * | 2004-10-15 | 2010-12-22 | Bayer HealthCare LLC | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
AU2005315430B2 (en) * | 2004-12-14 | 2010-05-27 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
EP1845081A4 (en) * | 2005-02-01 | 2009-03-25 | Takeda Pharmaceutical | amide |
AU2006210056A1 (en) * | 2005-02-07 | 2006-08-10 | F. Hoffmann-La Roche Ag | Inhibitors of diacylglycerol acyltransferase (DGAT) |
US20090215780A1 (en) * | 2005-04-19 | 2009-08-27 | Bayer Pharmaceuticals Corporation | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity |
CA2610188A1 (en) * | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
EP1912634A4 (en) * | 2005-07-29 | 2010-06-09 | Bayer Healthcare Llc | PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY |
CN101296914B (zh) * | 2005-08-26 | 2012-07-18 | 盐野义制药株式会社 | 具有ppar激动活性的衍生物 |
WO2007060140A2 (en) * | 2005-11-28 | 2007-05-31 | F. Hoffmann-La Roche Ag | Inhibitors of diacyglycerol acyltransferase (dgat) |
WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
SI2402317T1 (sl) * | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
WO2007121154A2 (en) * | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
US20070254952A1 (en) * | 2006-04-21 | 2007-11-01 | Yuguang Wang | Cannabinoid receptor modulators |
WO2007137107A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007137103A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
KR20090010092A (ko) | 2006-05-30 | 2009-01-28 | 아스트라제네카 아베 | Dgat1 억제제로서의 1,3,4-옥사디아졸 유도체 |
AU2007266796B2 (en) * | 2006-05-30 | 2011-02-10 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
JP2009539816A (ja) * | 2006-06-06 | 2009-11-19 | アストラゼネカ アクチボラグ | 化学化合物 |
ES2359653T3 (es) * | 2006-06-08 | 2011-05-25 | Astrazeneca Ab | Bencimidazoles y su uso para el tratamiento de la diabetes. |
GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611552D0 (en) * | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
WO2008047694A1 (fr) * | 2006-10-13 | 2008-04-24 | Aska Pharmaceutical Co., Ltd. | Procédé de fabrication d'un composé benzothiazole |
JP2010511058A (ja) * | 2006-11-29 | 2010-04-08 | アボット・ラボラトリーズ | ジアシルグリセロールo−アシルトランスフェラーゼ1型酵素の阻害薬 |
MX2009010925A (es) * | 2007-04-09 | 2009-11-02 | Scidose Llc | Combinaciones de estatinas y agente anti-obesidad. |
MX2009011754A (es) | 2007-04-30 | 2009-12-01 | Abbott Lab | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. |
MX2009011753A (es) | 2007-04-30 | 2009-12-01 | Abbott Lab | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. |
JP5464709B2 (ja) * | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン/ピペラジン誘導体 |
CN101678019B (zh) | 2007-06-08 | 2016-03-30 | 詹森药业有限公司 | 哌啶/哌嗪衍生物 |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
US8835437B2 (en) | 2007-06-08 | 2014-09-16 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
AU2008339570B2 (en) | 2007-12-20 | 2012-04-12 | Astrazeneca Ab | Carbamoyl compounds as DGAT1 inhibitors 190 |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8394823B2 (en) * | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
WO2009126624A1 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
EP2296659B1 (en) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2341924A4 (en) * | 2008-10-02 | 2013-01-23 | David Gladstone Inst | METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010084979A1 (en) * | 2009-01-23 | 2010-07-29 | Banyu Pharmaceutical Co.,Ltd. | Benzodiazepin-2-on derivatives |
AR075858A1 (es) | 2009-03-18 | 2011-05-04 | Schering Corp | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa |
KR20120037939A (ko) | 2009-06-19 | 2012-04-20 | 아스트라제네카 아베 | Dgat1의 억제제로서 피라진 카르복사미드 |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US20120172369A1 (en) | 2009-09-14 | 2012-07-05 | Ting Pauline C | Inhibitors of diacylglycerol acyltransferase |
RU2012149806A (ru) | 2009-11-05 | 2014-05-27 | Пирамал Энтерпрайзис Лимитед | Карбоксиоксазольные или тиазольные соединения в качестве ингибиторов dgat-1, пригодные для лечения ожирения |
EA037187B1 (ru) * | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
EP2552441B1 (en) | 2010-03-30 | 2016-05-04 | Novartis AG | Uses of dgat1 inhibitors |
WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
US9302996B2 (en) * | 2010-12-17 | 2016-04-05 | Mitsubishi Tanabe Pharma Corporation | Continuous arycyclic compound |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102757420B (zh) * | 2011-04-28 | 2015-02-04 | 中国科学院上海药物研究所 | 联杂芳基羧酸类化合物、其制备方法,包含该化合物的药物组合物、及用途 |
KR20130013199A (ko) | 2011-07-27 | 2013-02-06 | 한미약품 주식회사 | 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
TW201317229A (zh) * | 2011-09-14 | 2013-05-01 | Daiichi Sankyo Co Ltd | 稠合雜環衍生物 |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN103059014B (zh) * | 2011-10-21 | 2016-05-18 | 北京韩美药品有限公司 | 新型杂芳基氨基衍生物 |
MA37385B1 (fr) | 2012-04-06 | 2019-09-30 | Pfizer Inc Etat De Delaware | Inhibiteurs de diacylglycérol-acyltransférase 2 |
JP5721032B2 (ja) * | 2012-06-15 | 2015-05-20 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP5977349B2 (ja) | 2012-06-15 | 2016-08-24 | 田辺三菱製薬株式会社 | 芳香族複素環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
AP2016009407A0 (en) | 2014-03-17 | 2016-08-31 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
EP3510031B1 (en) * | 2016-09-09 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
EP3305786A3 (de) | 2018-01-22 | 2018-07-25 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
EP4039676A4 (en) * | 2019-10-02 | 2024-04-03 | Klotho Sciences | COMPOUND INTENDED TO INDUCE THE EXPRESSION OF AN ANTI-AGING KLOTHO GENE AND USE THEREOF |
CA3168543A1 (en) * | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2023085931A1 (en) | 2021-11-11 | 2023-05-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatic organoids |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112840A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-buttersaeuren,ihre Salze und Ester |
US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
US3997589A (en) | 1971-03-17 | 1976-12-14 | Boehringer Ingelheim Gmbh | 4-(2'-Fluoro-4-biphenylylr-4-oxo-butyric acid and esters and salts thereof |
US4021479A (en) | 1971-03-17 | 1977-05-03 | Boehringer Ingelheim Gmbh | Derivatives of 4-(4-biphenylyl)-butyric acid |
DE2112716A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
DE2112715A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-hydroxybuttersaeuren,ihre Salze,Ester und Lactone |
DE3825617C2 (de) | 1988-07-28 | 1993-11-18 | W D Schumacher | Einrichtung zur Entfernung von Schmutz oder anderen Verunreinigungen |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
GB2276162A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benazilide derivatives |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US5886022A (en) | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
EP1090026B1 (en) | 1998-06-24 | 2008-08-27 | The J. David Gladstone Institutes | Diacylglycerol o-acyltransferase |
EP1098962B1 (en) | 1998-07-02 | 2009-09-09 | Calgene LLC | Diacylglycerol acyl transferase proteins |
US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
EP1031349A1 (en) | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
MXPA01012317A (es) | 2000-12-28 | 2002-07-22 | Warner Lambert Co | Prueba de aciltransferasa del diacilglicerol (dgat). |
-
2004
- 2004-04-30 AR ARP040101491A patent/AR044152A1/es unknown
- 2004-05-06 JP JP2006532796A patent/JP4759517B2/ja not_active Expired - Fee Related
- 2004-05-06 AT AT04751430T patent/ATE518841T1/de not_active IP Right Cessation
- 2004-05-06 NZ NZ543993A patent/NZ543993A/en unknown
- 2004-05-06 RU RU2005138134/04A patent/RU2357959C2/ru not_active IP Right Cessation
- 2004-05-06 MX MXPA05012061A patent/MXPA05012061A/es unknown
- 2004-05-06 US US10/839,833 patent/US7091228B2/en not_active Expired - Fee Related
- 2004-05-06 ES ES04751430T patent/ES2369220T3/es active Active
- 2004-05-06 BR BRPI0410170-7A patent/BRPI0410170A/pt not_active IP Right Cessation
- 2004-05-06 CA CA002524470A patent/CA2524470A1/en not_active Abandoned
- 2004-05-06 KR KR1020057021232A patent/KR20060009916A/ko not_active Application Discontinuation
- 2004-05-06 EP EP04751430A patent/EP1633722B1/en not_active Not-in-force
- 2004-05-06 CN CNA2004800191925A patent/CN1816531A/zh active Pending
- 2004-05-06 WO PCT/US2004/014036 patent/WO2004100881A2/en active Application Filing
- 2004-05-06 CL CL200400969A patent/CL2004000969A1/es unknown
- 2004-05-06 AU AU2004238258A patent/AU2004238258A1/en not_active Abandoned
- 2004-05-07 UY UY28314A patent/UY28314A1/es not_active Application Discontinuation
- 2004-05-07 GT GT200400092A patent/GT200400092A/es unknown
- 2004-05-07 TW TW093112839A patent/TW200510334A/zh unknown
- 2004-05-07 PE PE2004000471A patent/PE20050265A1/es not_active Application Discontinuation
-
2005
- 2005-11-24 MA MA28625A patent/MA27843A1/fr unknown
- 2005-12-06 ZA ZA200509883A patent/ZA200509883B/en unknown
- 2005-12-08 NO NO20055832A patent/NO20055832L/no not_active Application Discontinuation
- 2005-12-09 EC EC2005006210A patent/ECSP056210A/es unknown
-
2006
- 2006-01-27 US US11/341,197 patent/US7423156B2/en not_active Expired - Fee Related
-
2008
- 2008-08-04 US US12/185,813 patent/US20090197795A1/en not_active Abandoned
- 2008-09-05 US US12/231,878 patent/US8013166B2/en not_active Expired - Fee Related
- 2008-09-08 US US12/206,721 patent/US7968576B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05012061A (es) | Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad. | |
TNSN07111A1 (en) | Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity. | |
WO2006113919A3 (en) | Aryl alkyl acid derivatives for and use thereof | |
WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
TW200628473A (en) | Novel heterocycles | |
MXPA05007462A (es) | Derivados de pirrolopiridazina. | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
MXPA05008438A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
WO2007076087A3 (en) | 3-aryl-substituted quinazolones, and uses thereof | |
MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
SI1606288T1 (sl) | Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine | |
TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
NO20032411D0 (no) | Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens | |
EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
UA86051C2 (en) | Substituted quinoline compounds |